How do you decide between enrolling an oligometastatic NSCLC patient on LU-002 versus treating them with SBRT off trial?
Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to a study that has an arm with documented worse survival?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · University of Texas Southwestern Medical Center
Answered on
On behalf of @Dr. First Last, MD, PhD and @Dr. First Last, MD
This question is very important and goes towards the question of equipoise from the perspective of the physician and patient for enrollment on NRG-LU002, accounting for recent data from Gomez et al and Palma et al presented at ASTRO 2018. ...
Join for free or sign in to see the full answer